Patient Response to Treatment With FTX-6058

Pharmacy Times^® interviewed Christopher Moxham, the senior vice president of discovery research at Fulcrum Therapeutics, on his presentation at the 62nd ASH Annual Meeting and Exposition. The presentation discusses research into the induction of fetal hemoglobin by FTX6058, a novel small molecule development candidate.

In this video, Moxham explains the results observed in his research when treating donors who were healthy or had sickle cell disease with FTX-6058.